Yasushi Yatabe

Journal of Thoracic Oncology · 2004–2022

A researcher in the Science corpus: 18 papers; trusts 0 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Whom Yasushi Yatabe trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. William Pao

Who trusts Yasushi Yatabe overall

1. Carlo Maria Croce
2. George A. Calin

Papers from Yasushi Yatabe's perspective

Ordered by how strongly the researchers Yasushi Yatabe trusts endorse each paper. Same corpus, a different order for every researcher.

1. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (Journal of Clinical Oncology)
2. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
3. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy (Science)
4. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
5. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (PLoS Medicine)
6. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. (Journal of the American Medical Association (JAMA))
7. Pathology and genetics of tumours of the lung , pleura, thymus and heart
8. RET, ROS1 and ALK fusions in lung cancer (Nature Medicine)
9. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
10. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib (Proceedings of the National Academy of Sciences of the United States of America)

Their papers

• Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival (2004) — 2,552 citations
• A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. (2005) — 1,484 citations
• Reduced expression of Dicer associated with poor prognosis in lung cancer patients (2005) — 652 citations
• Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. (2008) — 647 citations
• Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. (2022) — 777 citations
• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology (2018) — 922 citations
• PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project (2018) — 689 citations
• The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part‐Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer (2016) — 650 citations
• Comprehensive genomic profiles of small cell lung cancer (2015) — 2,050 citations
• The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. (2015) — 3,963 citations
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (2011) — 4,028 citations
• International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. (2011) — 677 citations
• EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. (2010) — 1,200 citations
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. (2010) — 4,044 citations
• Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer (2007) — 615 citations
• Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib (2006) — 605 citations
• Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. (2005) — 960 citations
• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer (2004) — 1,264 citations